Profile cover photo
Profile photo
Capricor Therapeutics, Inc.
4 followers -
Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases.
Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases.

4 followers
About
Capricor Therapeutics, Inc.'s posts

Post has attachment

Post has attachment

Post has attachment

Post has attachment
Capricor in attendance for Duchenne Research Roundtable January 30th. http://ow.ly/XHNRA

Post has attachment
HOPE-DMD Trial is currently recruiting participants.

The HOPE-DUCHENNE trial will evaluate CAP-1002, cardiosphere derived stem cells, for the first time in boys with Duchenne Muscular Dystrophy who have significant involvement of their heart. The trial is designed as a randomized open-label usual care controlled multi-center study evaluating the safety and preliminary efficacy of CAP-1002 in up to 24 subjects.
For more information about HOPE-DUCHENNE, please visit: https://clinicaltrials.gov/ct2/show/NCT02485938?term=capricor&rank=1
Please refer to this study by its ClinicalTrials.gov identifier: NCT02485938

Post has attachment
Webinar: HOPE-Duchenne Trial going on now! Register to view webinar.
@ParentProjectMD @Capricor_News https://t.co/Nuo8Kd4bsu

Post has attachment
Capricor Therapeutics to Present at Biotech Showcase 2016. Register to watch the webcast at 4 pm PST today http://ow.ly/WUuCp

Post has attachment
Webinar: HOPE-Duchenne Trial - Capricor Therapeutics http://ow.ly/WLQ9y

Post has attachment

Post has attachment
Wait while more posts are being loaded